Pred Forte®
Prednisolone Acetate 1.0% · ophthalmic suspension
Steroid
Approved uses
Steroid-responsive inflammation of the conjunctiva, cornea, and anterior segment
1 to 2 drops into the conjunctival sac 2 to 4 times daily, frequency increased during the initial 24 to 48 hours if needed
At 8 doses daily, anterior chamber cells fall 2 grades by day 14 and clear completely in 64% by day 21.
OFF-LABELNot in the FDA label for this product
Maintenance steroid after Descemet membrane endothelial keratoplasty, for rejection prophylaxis
Trial regimen, 1% suspension QID for 2 months, TID for 1 month, BID for 1 month, then QD for 7 months, started 1 month after DMEK
RCT · n=233 · higher IOP rise
Prospective randomized evaluator-masked trial, 167 patients randomized 1 to 1 at one month after DMEK with 66 fellow eyes assigned to the opposite treatment, 233 eyes in total. No immunologic rejection episode occurred in either arm (0%, P = 1). IOP elevation (IOP 24 mmHg or higher, or a rise of 10 mmHg or more over preoperative baseline) occurred in 25% of prednisolone-treated eyes versus 11% of loteprednol etabonate 0.5% gel eyes (relative risk 2.3, 95% CI 1.2 to 4.5, P = 0.016); the authors concluded loteprednol gel was as effective at preventing rejection and significantly less likely to raise IOP.
Contraindications
- Acute untreated purulent ocular infection
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any ingredient of the preparation or to other corticosteroids
1% suspension, 1 mL in 5 mL bottle, 5 mL in 10 mL bottle, 10 mL in 15 mL bottle, 15 mL in 15 mL bottle
Glucocorticoid with 3 to 5 times the anti-inflammatory potency of hydrocortisone on a weight basis. Inhibits the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation.
Warnings & Precautions
- Elevated IOP: Prolonged use may increase IOP in susceptible individuals, producing glaucoma with optic nerve damage and defects in visual acuity and fields of vision; monitor IOP routinely when used 10 days or longer, even though it may be difficult in children and uncooperative patients; use with caution in the presence of glaucoma, and check IOP frequently.
- Posterior subcapsular cataract: Prolonged corticosteroid use may produce cataract formation.
- Secondary ocular infection: Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections; acute purulent infections of the eye may be masked or their activity enhanced.
- Corneal and scleral thinning: Various ocular diseases and long-term topical corticosteroid use have been known to cause thinning, and use over thin corneal or scleral tissue may lead to perforation.
- Fungal invasion: Suspect fungal infection in any persistent corneal ulceration where a corticosteroid has been used or is in use, and take fungal cultures when appropriate.
- Prescription renewal: The initial prescription and renewal of the medication order beyond 20 mL should be made by a physician only after examination with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining; re-evaluate the patient if signs and symptoms fail to improve after 2 days.
- Viral infection exacerbation: Ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye including herpes simplex; a history of herpes simplex requires great caution, and frequent slit lamp microscopy is recommended.
- Delayed healing after cataract surgery: Steroid use may delay healing and increase the incidence of bleb formation.
- Sulfite sensitivity: Contains sodium bisulfite, which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people; sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people, and its overall prevalence is unknown and probably low.
- Absorption by soft contact lenses: Contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove lenses before application, and they may be reinserted 15 minutes after administration.
- Eye injury or contamination: Avoid touching the bottle tip to eyelids or to any other surface to prevent eye injury or contamination; use of the bottle by more than one person may spread infection.
Common Side Effects
Reported adverse reactions include elevated IOP with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, delayed wound healing, and secondary ocular infection (bacterial, fungal, and viral). Other reported reactions include allergic reactions, dysgeusia, eye pain, foreign body sensation, headache, pruritus, rash, transient burning and stinging upon instillation and other minor symptoms of ocular irritation, urticaria, and visual disturbance (blurry vision). Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids, and corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe.
Pregnancy: Prednisolone has been shown to be teratogenic in mice at doses 1 to 10 times the human dose. When dexamethasone, hydrocortisone, and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation, a significant increase in the incidence of cleft palate was observed in the fetuses. There are no adequate well-controlled studies in pregnant women, so use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Unknown whether topical ophthalmic corticosteroid produces detectable quantities in breast milk; systemically administered corticosteroids do appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects, so weigh discontinuing nursing against discontinuing the drug.
Safety and effectiveness established in pediatric patients.